CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | pCODR 10178 |
|---|---|
| Brand Name | TBD |
| Generic Name | Bevacizumab |
| Tumour Type | Gastrointestinal / Lung |
| Indication | Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer Biosimilar |
| Funding Request | Metastatic Colorectal Cancer (mCRC); Non-Small Cell Lung Cancer (NSCLC) |
| Review Status | File Closed |
| Pre Noc Submission | Yes |
| NOC Date | |
| Manufacturer | Pfizer Canada Inc. |
| Sponsor | Pfizer Canada Inc. |
| Submission Date | March 14, 2019 |
| Submission Deemed Complete | March 28, 2019 |
| Submission Type | Biosimilar – New Drug |
| Prioritization Requested | |
| Stakeholder Input Deadline ‡ | March 28, 2019 |
| Check-point meeting (target date) | |
| pERC Meeting (target date) | |
| Initial Recommendation Issued (target date) | |
| Feedback Deadline (target date) ‡ | |
| pERC Reconsideration Meeting (target date) | |
| Final Recommendation Issued (target date) | |
| Notification to Implement Issued |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.